AI supported in silico screening of chimeric antigen receptor therapy targets
Chimeric antigen receptor (CAR) cell therapy has achieved transformative clinical success through targeting of CD19 in refractory B cell malignancies, but extension of this strategy to solid tumors, other hematological malignancies, and autoimmune disease has exposed the complexity of target selection. Antigen abundanc...